This is a working overview of trans-3-hexenoyl, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
== History == The presence of autoantibodies against citrullinated proteins in rheumatoid arthritis patients was first described in the mid-1970s when the biochemical basis of antibody reactivity against keratin and filaggrin was investigated. Subsequent studies demonstrated that autoantibodies from RA patients react with a series of different citrullinated antigens, including fibrinogen, deiminated Epstein–Barr virus nuclear antigen 1 and vimentin, which is a member of the intermediate filament family of proteins. Several assays for detecting ACPAs were developed in the following years, employing mutated citrullinated Vimentin (MCV-assay), filaggrin-derived peptides (CCP-assay) and viral citrullinated peptides (VCP-assay). A 2006 clinical study showed that anti viral citrullinated peptide (VCP) antibodies of the IgG and IgA isotypes represent a discriminating specific marker of rheumatoid arthritis from other chronic arthritides and disease controls, suggesting an independent production of each isotype. In 2010, ACPA testing has become substantial part of The 2010 ACR-EULAR classification criteria for rheumatoid arthritis.
Atypical chronic pain syndrome Body dysmorphic disorder (dysmorphic syndrome, dysmorphophobia) Brachioradial pruritus Bromidrosiphobia Complex regional pain syndrome (reflex sympathetic dystrophy) Congenital insensitivity to pain with anhidrosis Delusional parasitosis (delusions of parasitosis, Ekbom syndrome, monosymptomatic hypochondriacal psychosis) Dermatothlasia Dermatitis artefacta (factitious dermatitis, factitial dermatitis) Glossodynia (burning mouth syndrome, burning tongue, orodynia) Levator ani syndrome Malum perforans pedis (neurotrophic ulcer, perforating ulcer of the foot) Meralgia paresthetica (Roth–Bernhardt disease) Neurotic excoriations Notalgia paresthetica (hereditary localized pruritus, posterior pigmented pruritic patch, subscapular pruritus) Postencephalitic trophic ulcer Psychogenic pruritus Riley–Day syndrome (familial dysautonomia) Scalp dysesthesia Sciatic nerve injury Scrotodynia Syringomyelia (Morvan's disease) Traumatic neuroma (amputation neuroma) Trichotillomania (trichotillosis) Trigeminal neuralgia (tic douloureux) Trigeminal trophic lesion (trigeminal trophic syndrome) Vulvodynia (vestibulodynia)
Treatment depends on the underlying cause. In general, exercise, particularly of the aerobic type, is effective for preventing ED during midlife. Counseling can be used if the underlying cause is psychological, including how to lower stress or anxiety related to sex. Medications by mouth and vacuum erection devices are first-line treatments, followed by injections of drugs into the penis, as well as penile implants. Vascular reconstructive surgeries are beneficial in certain groups. Treatments, other than surgery, do not fix the underlying physiological problem, but are used as needed before sex.
=== „Du sollst“ (2005) === Published in 2005, Du sollst [Thou Shalt] is Kermani's first literary work that does not features a first-person narrator. Narrated by an uninvolved narrator, the text provides insights into the most intimate moments of ten heterosexual couples (with a slight preponderance of the male perspective). We do not learn much about the characters' lives; not even their names are mentioned. Instead, the text focuses on brief sex and bedroomscenes – echoing Arthur Schnitzler's controversial play La Ronde. The narrative focuses less on sexual practices and more on the conversations and thoughts that unfold during these encounters. An insurmountable closeness, as it were, marks almost all of the relationships. Apart from one short story in which the possibility of symmetrical and emphatic love appears [“Honor Thy Father and Mother”], the relationships presented are characterized by misunderstandings and deceptions, fears and dependencies, power struggles and violence. At the height of physical union, many of the characters feel a painful loneliness—this dialectic of love being the subject of the texts' special psycho-microscopic attention. The first ten stories are each preceded by one of the Ten Commandments, to which the texts refer with varying degrees of directness.
Sources: en.wikipedia.org
Automated peptide synthesis involves the condensation of the amino group of protected amino acids with the activated ester. HOBt is used to produce such activated esters which react with amines at ambient temperature to give amides. HOBt is also used for the synthesis of amides from carboxylic acids aside from amino acids. These substrates may not be convertible to the acyl chlorides.
In 2001, various tyrannosaurid teeth and a metatarsal unearthed in a quarry near Zhucheng, China, were assigned by Chinese paleontologist Hu Chengzhi to the newly erected species Tyrannosaurus zhuchengensis. However, in a nearby site, a right maxilla and left jawbone were assigned to the newly erected tyrannosaurid genus Zhuchengtyrannus in 2011. It is possible that T. zhuchengensis is synonymous with Zhuchengtyrannus. In any case, T. zhuchengensis is considered to be a nomen dubium as the holotype lacks diagnostic features below the level Tyrannosaurinae. In 2006, a fragmentary tyrannosaurid lacrimal (CM 9401) from the Judith River Formation of Fergus County, Montana, was described as ?Tyrannosaurus sp. This isolated right lacrimal was originally collected alongside the holotype specimen of Deinosuchus rugosus, a giant crocodilian, and remained undescribed until its re-identification as belonging to a tyrannosaurid theropod in the 1980s by paleontologist Dale Russell. The lacrimal closely resembles those of Tyrannosaurus rex in both size and morphology. Notably, it lacks the "lacrimal horn" typically present in earlier tyrannosaurids like Albertosaurus and Gorgosaurus, instead exhibiting a distinct rugosity along the dorsal surface—consistent with T. rex and its Asian relative Tarbosaurus. The specimen's considerable size places it within the range of known T. rex individuals, suggesting the presence of large tyrannosaurids during the Campanian stage (~75 million years ago), a temporal range earlier than the established Maastrichtian age (~68–66 Ma) for Tyrannosaurus rex.
== In proteins == Selenium and sulfur are chalcogens that share many chemical properties so the substitution of methionine with selenomethionine may have only a limited effect on protein structure and function. Indeed, bacteria can tolerate a very high amount of substitution of this kind.
==== Doggie Kruger ==== Anubian Doggie Kruger (アヌビス星人ドギー・クルーガー, Anubisu Seijin Dogī Kurūgā), also known as "Boss" (ボス, Bosu) to several of his subordinates, is from Planet Anubis and is the tough-yet-honorable superintendent of the Space Police's Metropolitan Police, as well as chief of its Earth branch. While operating as a Dekaranger in his younger years, he earned a legendary reputation as "Hell's Guard Dog" (地獄の番犬, Jigoku no Banken), due in part to his willingness to do anything to save those he cares about. Despite this, he displays feelings for his assistant Swan and panics whenever he hears she has an admirer. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kruger investigated the alleged corruption of his superior Kight Reidlich, and was framed for murder and held captive for two years before his team rescues him in the present. Soon after, Kruger admits his feelings for Swan. In battle, Kruger is a practitioner of the Galaxy Sword-Style (銀河一刀流, Ginga Ittō-ryū) where he learned the style's secret technique, the Vega Impulse (ベガインパルス, Bega Inparusu). Though he is capable of destroying 100 foes without being defeated, he suffered from a spinal problem that caused him to miss once every 2000 attacks until being cured by chiropractor Yukito Sanjyo of the Abarangers. Additionally, utilizing a variant of the SP License called the Master License (マスターライセンス, Masutā Raisensu), Kruger can transform into the black-colored Deka Master (デカマスター, Deka Masutā).
In July 2023, TikTok launched a new streaming service called TikTok Music. This service allowed users to listen to, download and share songs. After a dispute with TikTok regarding payouts for artists and regulation of AI-generated music content on the platform, Universal Music Group decided not to renew its licensing agreement, causing its catalogue of 3 million recordings to become unavailable for usage after 2024. This marked the company's first instance of withdrawing its music from a major platform, in contrast to Warner Music, which had recently renewed its own licensing deal with TikTok. In March 2024, Universal Music Publishing Group removed its catalogue of 4 million compositions from TikTok. In April 2024, Taylor Swift's music returned to the platform. TikTok Music was discontinued in November 2024. In December 2025, TikTok launched digital gift cards. In February 2026, TikTok launched Local Feed, a feature intended to help users connect with their community and discover local events and updates. In June 2026, TikTok launched Agentic Hub, a platform that integrates third-party AI applications with its advertising system to support campaign creation, management, and performance evaluation. In July 2026, TikTok introduced new AI literacy measures, including educational guides and enhanced content transparency tools, to help users recognize AI-generated content. In August 2026, TikTok introduced a legacy account setting that allows users to decide what happens to their account after their death.
Sources: en.wikipedia.org
RSeH + H2O2 → RSeOH + H2O RSeOH + GSH → GS-SeR + H2O GS-SeR + GSH → GS-SG + RSeH In the absence of thiols, selenols tend to overoxidize to produce seleninic acids. Many organoselenium compounds (selenenamides, diaryl diselenides) contain "interesting" biological activities. Their activity is attributed to their mimicry of glutathione peroxidase activity. They reduce hydroperoxides that otherwise convert to toxic byproducts and/or reactive oxygen species that can cause further damage to the cell.
Some proteins never fold in cells at all except with the assistance of chaperones which either isolate individual proteins so that their folding is not interrupted by interactions with other proteins or help to unfold misfolded proteins, allowing them to refold into the correct native structure. This function is crucial to prevent the risk of precipitation into insoluble amorphous aggregates. The external factors involved in protein denaturation or disruption of the native state include temperature, external fields (electric, magnetic), molecular crowding, and even the limitation of space (i.e. confinement), which can have a big influence on the folding of proteins. High concentrations of solutes, extremes of pH, mechanical forces, and the presence of chemical denaturants can contribute to protein denaturation, as well. These individual factors are categorized together as stresses. Chaperones are shown to exist in increasing concentrations during times of cellular stress and help the proper folding of emerging proteins as well as denatured or misfolded ones. Under some conditions proteins will not fold into their biochemically functional forms. Temperatures above or below the range that cells tend to live in will cause thermally unstable proteins to unfold or denature (this is why boiling makes an egg white turn opaque).
=== Hydrogen bromide === The simplest compound of bromine is hydrogen bromide, HBr. It is mainly used in the production of inorganic bromides and alkyl bromides, and as a catalyst for many reactions in organic chemistry. Industrially, it is mainly produced by the reaction of hydrogen gas with bromine gas at 200–400 °C with a platinum catalyst. However, reduction of bromine with red phosphorus is a more practical way to produce hydrogen bromide in the laboratory:
== Problems and current disadvantages == A primary issue accompanying BsAb development since the early stages has been achieving a high ratio of correctly paired bispecific antibodies. Early attempts to produce BsAbs resulted in large amounts of homodimers and other mispaired fragments. Novel pairing technologies have been developed to increase the heterodimerization rate, leading to higher yields and reduced production costs. Furthermore, IgG-like antibodies can be immunogenic, which means the Fc region could cause detrimental downstream immune responses caused by cells that are activated by Fc receptors. The therapeutic use of BsAbs as a whole is still largely in development, with many clinical trials currently ongoing that are determining the efficacy and safety of BsAbs for treatment. One major area of concern is the feasibility of administration and management of side effects, where the potential for therapeutic success must be weighed against possible risks. The occurrence of side effects primarily depends on the specific antibody, its target, and patient-specific factors. These factors have to be individually examined for each patient in order to evaluate the feasibility of a bispecific antibody treatment, and to assess the risk of infusion-related, immune-related, organ-specific, and hematologic side effects.
=== Plasma in clinical diagnosis === Plasma contains an abundance of proteins many of which can be used as biomarkers, indicating the presence of certain diseases in an individual. Currently, 2D Electrophoresis is the primary method for discovery and detection of biomarkers in plasma. This involves the separation of plasma proteins on a gel by exploiting differences in their size and pI. Potential disease biomarkers may be present in plasma at very low concentrations, so, plasma samples must undergo preparation procedures for accurate results to be obtained using 2D Electrophoresis. These preparation procedures aim to remove contaminants that may interfere with detection of biomarkers, solubilize the proteins so they are able to undergo 2D Electrophoresis analysis, and prepare plasma with minimal loss of low concentration proteins, but optimal removal of high abundance proteins. The future of laboratory diagnostics are headed toward lab-on-a-chip technology, which will bring the laboratory to the point-of-care. This involves integration of all of the steps in the analytical process, from the initial removal of plasma from whole blood to the final analytical result, on a small microfluidic device. This is advantageous because it reduces turn around time, allows for the control of variables by automation, and removes the labor-intensive and sample wasting steps in current diagnostic processes.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.